Teva announced the launch of Raloxifene Hydrochloride Tablets, the generic version of Eli Lilly’s Evista.

Raloxifene is a selective estrogen receptor modulator (SERM), which has biological actions mediated through estrogen receptor binding. It can act as either an agonist or antagonist at different estrogenic tissues depending tissue-specific factors influencing the estrogen receptor gene. Raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women, and for the reduction in risk of invasive breast cancer in postmenopausal women that have osteoporosis and/or are at high risk for invasive breast cancer.

RELATED: Musculoskeletal Disorders Resource Center

Raloxifene Tablets are available in a 60mg dosage strength in 30-, 100-, and 1000-count bottles.

For more information call (888) 838-2872 or visit